Bifunctional complement inhibitor - BioCryst Pharmaceuticals
Latest Information Update: 28 Mar 2024
At a glance
- Originator BioCryst Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Alternative complement pathway inhibitors; Complement system protein inhibitors
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
